Alcobra Announces Leadership Update

TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) — Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that Dr. Yaron Daniely will be stepping down on May 31, 2017 as President and Chief Executive Officer to become the Chief Executive Officer of Yissum, the technology transfer company of the Hebrew University in Jerusalem, Israel. David Baker, currently Alcobra’s Chief Commercial Officer, will assume the position of interim CEO. Dr. Daniely will remain on the Board of Directors of Alcobra and will be actively involved in ensuring a seamless transition of duties and responsibilities.  The Company’s Board of Directors also announced that it has appointed Dr. Daniely as Chairman of the Board of Directors, effective June 1, 2017.